Needham & Company Downgrades Vertex (VRTX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Maxim Group Downgrades Vertex (VRTX) to Hold
January 29, 2015 7:30 AM ESTMaxim Group downgraded Vertex (NASDAQ: VRTX) from Buy to Hold with a price target of $121.00 (from $148.00).
Analyst Jason Kolbert commented:
Vertex reported YE2014 non-GAAP revenue and operating expenses of $536M and $920M, respectively, and a non-GAAP loss of $511M and EPS of ($2.17). Revenue was driven largely by Kalydeco sales of $464M. Vertex enters 2015 with... MoreVertex Pharma (VRTX) Posts Smaller Q4 Loss
January 28, 2015 4:11 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of ($0.55), $0.10 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $145 million versus the consensus estimate of $137.5 million.
"The potential approval and launch of the combination of lumacaftor and ivacaftor and continued label... More
